Relmada Therapeutics Inc. (RLMD)
0.26
0.00 (0.00%)
At close: Mar 03, 2025, 3:59 PM
0.24
-5.22%
After-hours: Mar 03, 2025, 06:03 PM EST
Company Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders.
Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.
The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 20, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Dr. Sergio Traversa M.B.A., Pharm.D. |
Contact Details
Address: 2222 Ponce de Leon Boulevard Coral Gables, Florida United States | |
| Website | https://www.relmada.com |
Stock Details
| Ticker Symbol | RLMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553643 |
| CUSIP Number | 75955J402 |
| ISIN Number | US75955J4022 |
| Employer ID | 45-5401931 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sergio Traversa M.B.A., Pharm.D. | Chief Executive Officer & Director |
| Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer |
| Paul E. Kelly M.B.A. | Chief Operating Officer & Director |
| Dr. Andrew Cutler | Senior Clinical Development Advisor |
| Dr. Richard M. Mangano Ph.D. | Consultant |
| Gina DiGuglielmo | Vice President & Head of Clinical Operations |
| John Hixon | Head of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 06, 2025 | 8-K | Current Report |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 06, 2025 | 8-K | Current Report |
| Dec 09, 2024 | 8-K | Current Report |
| Dec 04, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Oct 23, 2024 | 4 | Filing |
| Sep 11, 2024 | 4 | Filing |
| Sep 11, 2024 | 4 | Filing |